Exhibit 99.1 LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ● Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen® Program ● Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit ● OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting ● OPC1 Clinical Study Start Up Preparation ...